These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

374 related articles for article (PubMed ID: 35468049)

  • 1. Type 1 Diabetes Mellitus Associated with Nivolumab after Second SARS-CoV-2 Vaccination, Japan.
    Sato T; Kodama S; Kaneko K; Imai J; Katagiri H
    Emerg Infect Dis; 2022 Jul; 28(7):1518-1520. PubMed ID: 35468049
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Type 1 diabetes mellitus following SARS-CoV-2 mRNA vaccination.
    Aydoğan Bİ; Ünlütürk U; Cesur M
    Endocrine; 2022 Oct; 78(1):42-46. PubMed ID: 35809159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SARS-CoV-2 infection and COVID-19 vaccination in cancer patients undergoing immune checkpoint inhibitors.
    Yang Y; Xu G
    Cell Death Dis; 2023 Jun; 14(6):390. PubMed ID: 37391394
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The mRNA COVID-19 vaccine in patients with cancer receiving checkpoint inhibitor therapy: what we know and what we don't.
    Malek AE; Cornejo PP; Daoud N; Alam M
    Immunotherapy; 2022 Feb; 14(2):91-94. PubMed ID: 34747190
    [No Abstract]   [Full Text] [Related]  

  • 5. Graves' Disease after Administration of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine in a Type 1 Diabetes Patient.
    Sakai M; Takao K; Kato T; Ito K; Kubota S; Hirose T; Liu Y; Mizuno M; Hirota T; Suwa T; Horikawa Y; Yabe D
    Intern Med; 2022; 61(10):1561-1565. PubMed ID: 35569928
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Indications for and contraindications of immune checkpoint inhibitors in cancer patients with COVID-19 vaccination.
    Luo B; Li J; Hou X; Yang Q; Zhou Y; Ye J; Wu X; Feng Y; Hu T; Xu Z; He Y; Sun J
    Future Oncol; 2021 Sep; 17(26):3477-3484. PubMed ID: 34189948
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multisystem Inflammatory Syndrome in Children after SARS-CoV-2 Vaccination.
    Jain E; Donowitz JR; Aarons E; Marshall BC; Miller MP
    Emerg Infect Dis; 2022 May; 28(5):990-993. PubMed ID: 35275051
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Guillain-Barré Syndrome Associated with COVID-19 Vaccination.
    Finsterer J; Scorza FA; Scorza CA
    Emerg Infect Dis; 2022 May; 28(5):1079-1080. PubMed ID: 35447058
    [No Abstract]   [Full Text] [Related]  

  • 9. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and Immunogenicity of mRNA Vaccines Against Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Lung Cancer Receiving Immune Checkpoint Inhibitors: A Multicenter Observational Study in Japan.
    Hibino M; Uryu K; Takeda T; Kunimatsu Y; Shiotsu S; Uchino J; Hirai S; Yamada T; Okada A; Hasegawa Y; Hiranuma O; Chihara Y; Kamada R; Tobe S; Maeda K; Horiuchi S; Kondo T; Takayama K
    J Thorac Oncol; 2022 Aug; 17(8):1002-1013. PubMed ID: 35752437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diabetic ketoacidosis (DKA) in type 1 diabetes mellitus (T1DM) temporally related to COVID-19 vaccination.
    Ganakumar V; Jethwani P; Roy A; Shukla R; Mittal M; Garg MK
    Diabetes Metab Syndr; 2022 Jan; 16(1):102371. PubMed ID: 34954484
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Definite Acute Myocarditis After Coronavirus Disease 2019 mRNA Vaccination.
    Maeda M; Isawa T; Tada N
    Circ J; 2022 Mar; 86(4):724. PubMed ID: 34866122
    [No Abstract]   [Full Text] [Related]  

  • 13. Short-term safety of the BNT162b2 mRNA COVID-19 vaccine in patients with cancer treated with immune checkpoint inhibitors.
    Waissengrin B; Agbarya A; Safadi E; Padova H; Wolf I
    Lancet Oncol; 2021 May; 22(5):581-583. PubMed ID: 33812495
    [No Abstract]   [Full Text] [Related]  

  • 14. Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial.
    Chen GL; Li XF; Dai XH; Li N; Cheng ML; Huang Z; Shen J; Ge YH; Shen ZW; Deng YQ; Yang SY; Zhao H; Zhang NN; Zhang YF; Wei L; Wu KQ; Zhu MF; Peng CG; Jiang Q; Cao SC; Li YH; Zhao DH; Wu XH; Ni L; Shen HH; Dong C; Ying B; Sheng GP; Qin CF; Gao HN; Li LJ
    Lancet Microbe; 2022 Mar; 3(3):e193-e202. PubMed ID: 35098177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity.
    Chaudhary JK; Yadav R; Chaudhary PK; Maurya A; Kant N; Rugaie OA; Haokip HR; Yadav D; Roshan R; Prasad R; Chatrath A; Singh D; Jain N; Dhamija P
    Cells; 2021 Oct; 10(11):. PubMed ID: 34831172
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Severe Multisystem Inflammatory Symptoms in 2 Adults after Short Interval between COVID-19 and Subsequent Vaccination.
    Jenny-Avital ER; Howe RA
    Emerg Infect Dis; 2022 May; 28(5):1017-1020. PubMed ID: 35320702
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New-Onset Fulminant Type 1 Diabetes Following SARS-CoV-2 Protein Subunit Vaccine: A Case Report and Literature Review.
    Huang L; Liang M; He Y
    J Korean Med Sci; 2023 Jun; 38(24):e209. PubMed ID: 37337812
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nivolumab-induced fulminant type 1 diabetes with precipitous fall in C-peptide level.
    Miyauchi M; Toyoda M; Zhang J; Hamada N; Yamawaki T; Tanaka J; Harada K; Kashizaki F; Fukagawa M
    J Diabetes Investig; 2020 May; 11(3):748-749. PubMed ID: 31587459
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibody Responses to BNT162b2 Vaccination in Japan: Monitoring Vaccine Efficacy by Measuring IgG Antibodies against the Receptor-Binding Domain of SARS-CoV-2.
    Fujigaki H; Yamamoto Y; Koseki T; Banno S; Ando T; Ito H; Fujita T; Naruse H; Hata T; Moriyama S; Takahashi Y; Suzuki T; Murakami T; Yoshida Y; Yagura Y; Oyamada T; Takemura M; Kondo M; Iwata M; Saito K
    Microbiol Spectr; 2022 Feb; 10(1):e0118121. PubMed ID: 35044205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Seropositive rheumatoid arthritis after vaccination against SARS-CoV-2 infection.
    Baimukhamedov C; Makhmudov S; Botabekova A
    Int J Rheum Dis; 2021 Nov; 24(11):1440-1441. PubMed ID: 34585843
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 19.